5-azacytidine and 5-aza-2′-deoxycytidine (decitabine, DAC), a DNMT inhibitor, are used in the treatment in elderly patients with myelodysplastic syndromes (MDS) and AML [85]. Here, DNMT1 is linked to myelodysplastic syndrome.